Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation.
about
Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter-hypermethylation - the NCT Neuro Master Match (N2M2) pilot study.Treatment of glioblastoma in adultsAkt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma
P2860
Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Molecular differences in IDH w ...... to MGMT promoter methylation.
@en
Molecular differences in IDH w ...... to MGMT promoter methylation.
@nl
type
label
Molecular differences in IDH w ...... to MGMT promoter methylation.
@en
Molecular differences in IDH w ...... to MGMT promoter methylation.
@nl
prefLabel
Molecular differences in IDH w ...... to MGMT promoter methylation.
@en
Molecular differences in IDH w ...... to MGMT promoter methylation.
@nl
P2093
P2860
P50
P356
P1433
P1476
Molecular differences in IDH w ...... to MGMT promoter methylation.
@en
P2093
Ahmed Sadik
Anca-L Grosu
Angela Zacher
Anne Hertenstein
Christiane Opitz
Damian Stichel
David Jones
Dietmar Krex
Joachim Steinbach
Michael Platten
P2860
P356
10.1093/NEUONC/NOX160
P50
P577
2017-08-24T00:00:00Z